| Patient's ethnicity does not influence utilization of effective therapies in rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 16652419 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Biological agents have revolutionized the treatment of rheumatoid arthritis (RA). Given the previously documented ethnic disparity in the health service literature, we sought to determine if ethnic difference exists in the lag time between the diagnosis of RA and use of first biological agent. METHODS: RADIUS 1 and 2 are observational studies designed to document how rheumatologists treat RA across the United States. The sample analyzed here included early patients with RA who entered RADIUS with the initiation of the first biological agent. Ethnic status was categorized as White (W), African American (AA), and Hispanic (H). Lag time (months from RA diagnosis to initiation of the first biological agent) was the principal outcome variable. RESULTS: Compared to W (n=1616), AA (n=147) and H (n=116) were more likely to be female, younger, and have less than a high school education. Despite similar swollen and tender joint counts, AA and H had more active disease on the basis of Health Assessment Questionnaire and patient global assessments. Almost 97% of patients had some type of insurance coverage. On multivariable analysis, ethnic affiliation was not associated with lag time (14.5 months W vs 14.9 AA vs 14.3 H; p=NS). Similarly, there were also no significant ethnic differences in time to first DMARD (e.g., methotrexate) initiation. CONCLUSION: In a national sample of patients with RA, most of whom were insured, the length of time from diagnosis of RA to initiation of the first biological agent was not significantly different among Whites, African Americans, and Hispanics. |
| | |
Authors:
|
Dennis C Ang; Harold E Paulus; James S Louie |
Related Documents
:
|
17888499 - Sustained clinical response and high infliximab survival in psoriatic arthritis patient... 22995089 - Transcatheter aortic valve implantation: new developments and upcoming clinical trials. 19720679 - Hand deformities are important signs of disease severity in patients with early rheumat... 21091349 - Chlorhexidine controlled release profile following ethylene diamine tetraacetic acid ro... 23313969 - Ramosetron vs. ramosetron plus dexamethasone for the prevention of postoperative nausea... 23598749 - Corticotherapy response in primary iga nephropathy. 10768539 - Functional outcome in knee osteoarthritis after treatment with hylan g-f 20: a prospect... 11847599 - Mid-term results of aortic valve preservation: remodelling vs. reimplantation. 8360369 - Coping with oral surgery by self-efficacy enhancement and perceptions of control. |
Publication Detail:
|
Type: Comparative Study; Journal Article |
Journal Detail:
|
Title: The Journal of rheumatology Volume: 33 ISSN: 0315-162X ISO Abbreviation: J. Rheumatol. Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-05-02 Completed Date: 2006-08-09 Revised Date: 2007-03-06 |
Medline Journal Info:
|
Nlm Unique ID: 7501984 Medline TA: J Rheumatol Country: Canada |
Other Details:
|
Languages: eng Pagination: 870-8 Citation Subset: IM |
Affiliation:
|
Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-5100, USA. Dang@iupui.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult African Americans Antirheumatic Agents / therapeutic use* Arthritis, Rheumatoid / diagnosis, drug therapy*, ethnology*, physiopathology Ethnic Groups* European Continental Ancestry Group Female Hispanic Americans Humans Insurance, Major Medical Male Middle Aged Multivariate Analysis Patient Care Management / statistics & numerical data* Questionnaires Time Factors United States |
| Chemical | |
Reg. No./Substance:
|
0/Antirheumatic Agents |
| Comments/Corrections | |
Comment In:
|
J Rheumatol. 2007 Jan;34(1):233; author reply 233-4
[PMID:
17216694
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice...
Next Document: Survival analysis and longterm results of elbow synovectomy in rheumatoid arthritis.